Skip to main content

Table 2 Efficacy in cohorts A and B and according to bone involvement

From: Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

ParameterAll non Squamous (N/%)All Squamous (N/%)Non SquamousBoM+ (N/%)Non-SquamousBoM- (N/%)pSquamous BoM+ (N/%)Squamous
BoM- (N/%)
p
Response
 • CR12/14/17/15/1< 0.0001*0/04/20.04*
 • PR278/1765/1866/11212/2215/1350/20
 • SD414/26108/28137/22277/2925/2183/33
 • PD818/52189/50393/63425/4478/65111/44
 • NV66/45/323/343/42/23/1
Median PFS
(months/range)
3.0 (2.9–3.1)4.2 (3.4–5.0)3 (2.9–3.1)4 (3.5–4.5)< 0.00012.7 (2.2–3.2)5.2 (4.3–6.0)< 0.0001
12 months PFS (%)23271527< 0.00011531< 0.0001
Median OS
(months/range)
11.3 (10.2–12.4)7.9 (6.2–9.6)7.4 (6.0–8.8)15.3 (13.2—17.4)< 0.00015 (3.9–6.1)10.9 (8.4–13.4)< 0.0001
12 months OS (%)48393855< 0.00011948< 0.0001
  1. *p value was calculated in CR + PR versus SD + PD